Akero Therapeutics Inc AKRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKRO is a good fit for your portfolio.
News
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
-
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
-
AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action
-
Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm
-
Akero Therapeutics (AKRO) SYMMETRY Study Under Fire in Class Action – AKRO Investors with Substantial Losses Encouraged to Contact Hagens Berman by June 25, 2024
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, Akero, Equinix, and Harbor Diversified and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
-
AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the Firm
Trading Information
- Previous Close Price
- $20.62
- Day Range
- $20.27–21.51
- 52-Week Range
- $11.25–58.38
- Bid/Ask
- $20.30 / $21.80
- Market Cap
- $1.40 Bil
- Volume/Avg
- 626,009 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 58
- Website
- https://www.akerotx.com
Comparables
Valuation
Metric
|
AKRO
|
CBAY
|
PLRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.66 | 12.65 | 1.89 |
Price/Sales | — | 111.01 | 3,293.18 |
Price/Cash Flow | — | — | — |
Price/Earnings
AKRO
CBAY
PLRX
Financial Strength
Metric
|
AKRO
|
CBAY
|
PLRX
|
---|---|---|---|
Quick Ratio | 29.86 | 10.70 | 15.95 |
Current Ratio | 30.12 | 10.96 | 16.12 |
Interest Coverage | −57.10 | −5.27 | −138.69 |
Quick Ratio
AKRO
CBAY
PLRX
Profitability
Metric
|
AKRO
|
CBAY
|
PLRX
|
---|---|---|---|
Return on Assets (Normalized) | −24.65% | −30.06% | −23.39% |
Return on Equity (Normalized) | −26.81% | −51.97% | −25.61% |
Return on Invested Capital (Normalized) | −30.22% | −30.87% | −29.08% |
Return on Assets
AKRO
CBAY
PLRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wpvzcdnhm | Zmpml | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ccntjwnd | Xvsmqp | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nmhylkwv | Dgtfppy | $107.6 Bil | |
MRNA
| Moderna Inc | Vgctzqbm | Xqxjj | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Dmqmpmnnd | Klrn | $22.3 Bil | |
ARGX
| argenx SE ADR | Myztvxzv | Hzfl | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Glbvqjkkb | Fyxkl | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tkjmpbv | Ftsfd | $15.1 Bil | |
INCY
| Incyte Corp | Rtxswjmk | Cgwqbc | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bwlshnrsc | Zhytsx | $12.7 Bil |